Pages
Products
AAV PHP.S-CMV-Cre

AAV PHP.S-CMV-Cre

Cat.No. :  AAV00311Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV serotype PHP.S Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00311Z
Description AAV serotype PHP.S particles contain Cre recombinase under CMV promoter.
Serotype AAV serotype PHP.S
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Adeno-associated viruses (AAVs) have become one of the tools of choice for neuroscience research. Due to their ease of use and efficient delivery of a variety of gene products, including fluorescent proteins, AAVs have greatly facilitated the mapping and manipulation of brain neural circuits. Depending on the serotype, AAVs are effective in different brain regions, have specific uptake into neuronal and/or glial populations, and selectively transport anterogradely or retrogradely in CNS neurons. Stereotaxic injections at target sites, combined with the use of virally delivered or transgenic expressed Cre and Flp recombinases, allow for the construction of detailed maps of projections of selected neuronal populations and their functional interactions. To date, AAV-dependent manipulation of the peripheral nervous system has been greatly limited, although many open questions about connectivity would benefit from this approach. One difficulty is that the somata of these neurons are contained within relatively inaccessible dorsal root, cranial, or autonomic ganglia. Many studies have reported AAV-mediated transduction of peripheral neurons using various delivery methods, such as sciatic nerve injection, direct intraganglionic injection, and intrathecal infusion. However, these approaches are invasive and inefficient because the viral particles lack broad tropism for peripheral neurons. Another approach to preferentially transduce peripheral sensory neurons is to inject the virus into the blood circulation, taking advantage of the difficulty of AAV in crossing the blood-brain barrier. This approach alone does not completely limit transduction to peripheral neurons. A major advance came with the development of a synthetic neurotropic serotype, AAV.PHP.S, which was generated by directed evolution. A variant of the Cap gene of AAV9 was introduced, followed by repeated phenotypic selection to transdural sensory neurons. The resulting pseudotyped AAV-PHP.S particles, when introduced into the circulation, infected mostly or only peripherally located neurons.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Reliable and efficient tool

Using the AAV PHP.S-CMV-Cre significantly streamlined our functional genomics research and drug discovery studies. It's a reliable and efficient tool.

Germany

10/30/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction